

ASX Release

Australian FY25 Research and Development Tax Incentive refund released

Melbourne, Australia – 17 February 2026: Adherium Limited (ASX:ADR) (“Adherium” or “the Company”), a global leader in digital respiratory management and developer of the US FDA-cleared Hailie® Smartinhaler® is pleased to advise that the Australian Taxation Office (ATO) has released A\$887,136 to the Company under the Australian Federal Government’s Research and Development (R&D) Tax Incentive program.

In addition, the Company confirms that its FY25 New Zealand R&D tax credit claim of NZ\$242,026 has been lodged with Inland Revenue (IRD) and is expected to be received over the coming weeks.

These incentives relate to eligible research and development activities undertaken during FY25 and further strengthen the Company’s cash position.

Adherium CEO and Managing Director, Dawn Bitz said:

“We are grateful for the continued support provided through the Australian and New Zealand R&D tax incentive programs. These initiatives play an important role in enabling innovation by providing valuable non-dilutive funding, allowing us to advance our development programs efficiently and create long-term value for our investors.”

Learn more at **adherium.com**

This ASX announcement was approved and authorised for release by the Board of Adherium.

- ENDS -

Investor Enquiries

Adherium Limited
investors@adherium.com

Media Enquiries:

Haley Chartres
H^CK Director
haley@hck.digital



ASX Release

About Adherium (ASX: ADR):

Adherium is a provider of integrated digital health solutions and a worldwide leader in connected respiratory medical devices, with more than 180,000 sold globally. Adherium's Hailie® platform solution provides clinicians, healthcare providers and patients access to remotely monitor medication usage parameters and adherence, supporting reimbursement for qualifying patient management. The Hailie® solution includes a suite of integration tools to enable the capture and sharing of health data via mobile and desktop apps, Software Development Kit (SDK) and Application Programming Interface (API) integration tools, and Adherium's own broad range of sensors connected to respiratory medications. Adherium's Hailie® solution is designed to provide visibility to healthcare providers of medication use history to better understand patterns in patient respiratory disease. Learn more at

adherium.com